Melanoma is a type of skin cancer that begins in skin cells called melanocytes. Although it accounts for only about 1% of skin cancers, it causes a large majority of skin cancer deaths. Anti-PD-1 monoclonal antibodies like Merck's Keytruda and Bristol Myers Squibb's Opdivo are mostly used to treat melanoma and have significantly improved survival outcomes in patients with advanced melanoma. However, a subset of patients develop resistance to PD-1 inhibition.
The company we are profiling today is Replimune Group Inc. (REPL), a clinical-stage biotechnology company that has developed a treatment for anti-PD1 failed melanoma.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.